Abstract This study aims to investigate how well the Assessment of SpondyloArthritis international Society (ASAS)/Outcome Measures in Rheumatology Clinical Trials (OMERACT) core set and response criteria for ankylosing spondylitis (AS) have been implemented in randomized controlled trials (RCTs) testing pharmacological and nonpharmacological interventions. A systematic literature search was performed up to June 2013 looking for RCTs in patients with axial spondyloarthritis (SpA) (AS and non-radiographic axial SpA). The assessed domains and instruments belonging to the core sets for disease-controlling anti-rheumatic therapy (DC-ART) and symptom-modifying anti-rheumatic drugs (SMARDs) were extracted. Results were reported separately for those trials published until 2 years after the publication of the core set (1 April 2001; 'control trials') and those trials published at least 2 years after the publication date ('implementation trials'). One hundred twenty-three articles from 99 RCTs were included in the analysis, comparing 48 'control trials' and 51 'implementation trials'. Regarding DC-ART core set, the following domains were significantly more frequently assessed in the 'implementation group' in comparison to the 'control group': 'physical function' (100 vs 41.7 %; p≤0.001), 'peripheral joints/entheses' (100 vs 33.3 %; p≤0.001) and 'fatigue' (100 vs 0 %; p≤0.001). Three instruments were significantly more used in the 'implementation group': Bath Ankylosing Spondylitis Functional Index (BASFI) (100 vs 8.3 %; p=≤0.001), CRP (92.3 vs 58.3 %; p=0.01) and Bath Ankylosing Spondylitis Metrology Index (BASMI) (53.8 vs 0 %; p=0.001). Regarding SMARD core set domains, physical function (92 vs 23 %; p≤0.001) and fatigue (84 vs 17 %; p≤0.001), as well as the instruments BASFI (88 vs 14 %; p≤0.001) and BASMI (52 vs 0 %; p ≤ 0.001), increased significantly in the 'implementation group'. Twenty per cent of trials from the 'implementation group' but none from the 'control group' included all domains of the core set. In conclusion, this study provides evidence for the implementation of the ASAS/OMERACT core set in RCTs of both DC-ART and SMARD. This applies to the use of the domains and, to a lesser extent, to the specific instruments.
Introduction
Spondyloarthritis (SpA) refers to a group of chronic inflammatory rheumatic disorders, and ankylosing spondylitis (AS) is considered as the prototype of this group [1] . In an attempt to bring more homogeneity in outcome assessment in AS and to facilitate the conduct of clinical trials, the Assessment of SpondyloArthritis international Society (ASAS) has selected core sets of variables to include as standardised end points in clinical trials and clinical practice. These core sets have been endorsed by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) group [2] .
ASAS has defined three scenarios for core sets: (1) diseasecontrolling anti-rheumatic therapy (DC-ART), (2) symptommodifying anti-rheumatic drugs (SMARDs) and physical therapy and (3) clinical record keeping. The domains selected for all three core sets include 'physical function', 'pain', 'spinal mobility', 'spinal stiffness', 'fatigue' and 'patient's global assessment'. The DC-ART core sets and clinical record keeping further include 'peripheral joints/entheses' and 'acute phase reactants', and the core set for DC-ART includes 'radiographs of the spine'. In addition, specific instruments to assess each of these domains were chosen [3] .
It has been postulated that the definition of core sets and the choice of appropriate instruments, which were effective in 1999 [4] , have importantly facilitated the development and successful registration of new treatments in AS. However, it is difficult to prove if, and to what extent, the core sets have contributed to this. An indirect indication for the value of core sets in the development of new treatments could be the demonstration that the usage of domains and instruments has measurably increased after the description of the core sets (implementation). In rheumatoid arthritis, a recent study found evidence of uptake of the core set [5] .
However, the implementation of the ASAS/OMERACT core sets has so far not been evaluated. The main purpose of this systematic literature review, therefore, is to analyse and compare the usage of domains and instruments of the core sets before and after the publication of the original article (April 1999). In addition, we checked the implementation of ASAS response criteria.
Methods
In order to ensure the transparent and complete reporting of this systematic review, the PRISMA statement was used as guidance [6] . The research question was structured according the PICOT strategy: population, interventions, 'control group', outcome and study types. The 'population' was defined as trials in patients with a diagnosis of AS or SpA. The 'intervention group' was defined as trials with pharmacological and non-pharmacological interventions published after April 2001 (the date was defined 2 years after the publication date to ensure that there was sufficient time to include the core set measures in randomized controlled trials (RCTs)). The 'control group' was defined as trials with pharmacological and non-pharmacological interventions published before April 2001. 'Outcome' was defined as the domains and instruments in the core sets for SMARD/physical therapy and DC-ART. 'Study type' was confined to RCTs.
A systematic literature search was performed in PubMed, Medline and Embase electronic library databases to identify target studies using a comprehensive search strategy. The search was updated last on 18 June 2013, without limitation of years of publication.
Search strategy
Articles in English, French, German, Dutch, Portuguese or Spanish were selected for analysis. All of the descriptions and synonyms for AS and SpA were used in the search terms in order to identify all relevant studies. Details of search strategy terms for identification of studies can be found online as a supplementary web (Appendix).
Study selection
Two authors (WB and VN) independently screened each title and abstract in order to select the articles for inclusion in the review. They determined the eligibility of each article according to predefined selection criteria. The main inclusion criterion was RCTs including patients with AS and/or SpA. Since axial SpA constitutes a new term that includes patients with predominantly axial symptoms of SpA, studies with nonradiographic axial SpA patients were also included. Since some studies have included not only axial SpA patients but also patients with other rheumatic conditions, we have selected those studies in which at least an arbitrary 80 % of the patients were axial SpA patients.
If title and abstract provided insufficient information, the full article text was obtained and reviewed. Reasons to exclude studies were the following: the sole report of outcomes not included in the ASAS core set and the impossibility to obtain a full text. Disagreement between the reviewers regarding inclusion of the articles studies was resolved by consensus. The references of all included papers can be found online in the Appendix.
Data collection
The same two authors extracted the data from the included studies independently according to a predetermined and standardised outcome review matrix. Differences regarding data extraction were resolved by re-review and consensus discussion by the two primary reviewers. General data extracted included information about first author, publication year, study start date and end date, study duration, interventions, total number of patients randomized and number of AS/ SpA patients and primary outcome. The presence/absence of reported domains collected were the following: physical function, pain, spinal mobility, spinal stiffness, fatigue, patient's global assessment, peripheral joints/entheses, acute phase reactants and 'spine radiographs'.
All different instruments and outcomes described in each study were extracted and included in the analysis. The instruments that were noted for each domain were those included in the ASAS core set, and additional instruments that were considered belong to the same domains. Table 1 describes the domains and instruments according to the ASAS/OMERACT core set, as they were published originally in 1999 and with a minor modification to add additional instruments in 2009 [2, 3] .
If the composite measure Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was reported, we considered the following domains also as performed: fatigue, pain, spinal stiffness and peripheral joint/entheses, even though these were not separately reported. If the Bath Ankylosing Spondylitis Metrology Index (BASMI) was reported, we considered the domain spinal mobility as well as the instruments lateral spinal flexion, tragus-to-wall distance, modified Schober's test, intermalleolar distance and cervical rotation also as performed, regardless of whether they were separately reported. Additionally, measures for the evaluation of treatment response were extracted, including the response criteria ASAS 20 [7] , ASAS 40 [8] , ASAS 5/6 and BASDAI 50 and the disease-state ASAS partial remission.
Data analysis
First, all information retrieved from multiple articles but belonging to the same RCT was combined and considered as one RCT for the analysis. The data sets were analysed to compare the use of the outcome measures in RCTs before and after the publication of the core set.
Since the ASAS-endorsed response criteria were published in 2001 (ASAS 20 and ASAS partial remission) and in 2004 (ASAS 40 and ASAS 5/6), only studies published 2 years after those dates were included in the assessment of these criteria in order to give time for the implementation. The number of trials assessing all domains of the core set was analysed for interventions and 'control group', in trials evaluating interventions with synthetic disease-modifying antirheumatic drugs (DMARDs), biologics and glucocorticoids as well as trials with other types of interventions including NSAIDs. In order to illustrate the evolution of the representation of domains and instruments over time, two figures were constructed.
For descriptive purposes, results were presented as means and standard deviations or medians for continuous variables and as frequencies (percentages) for categorical variables. The Student's t test for independent samples and chi-square tests (and Fisher's exact test if necessary) were used to compare continuous and dichotomous variables between implementation and 'control groups', respectively. Statistical analysis was done using SPSS software version 18.0. 
Results

Results of the search
The search strategy generated a total of 566 articles. Of these, 127 articles reporting the results of 99 clinical trials fulfilled the eligibility criteria. Reasons to exclude studies are mentioned in the flow chart. An important reason to exclude was that the clinical outcomes we were interested in were not reported (n=15). A summary of the search results is depicted in Fig. 1 .
Characteristics of the RCTs
Forty-eight of the 99 RCTs fell in the group of 'control trials' and 51 in the group of 'implementation trials'. A total of 12,261 patients, 94 % (n=11,497) of those having a diagnosis of AS and 2 % (n = 251) having a diagnosis of nonradiographic axial SpA, were included in the trials. The remaining patients (4 %, n=513) had a diagnosis of another rheumatic condition such as another SpA subtype (psoriatic arthritis, undifferentiated SpA and reactive arthritis), rheumatoid arthritis and osteoarthritis. The median number of AS patients per trial was similar (60 vs 61) in the 'control' vs the 'implementation group'. Median study duration was slightly higher in the 'control group' in comparison to the 'implementation group' (20 vs 16 weeks). Trials evaluating the efficacy of NSAIDs (52 vs 8 %; p ≤ 0.001) and DMARDs (21 vs 6 %; p = 0.06) were more frequently found in the 'control group' as compared to the 'implementation group'. However, trials evaluating biological drugs (45 vs 0 %; p≤0.001) and also physical therapy (27 vs 10 %; p=0.03) were more frequently represented in the 'implementation group' as compared to the 'control group'. The main characteristics of the RCTs in both groups are shown in Table 2 .
In trials evaluating interventions with DMARDs, biologics and glucocorticoids, five out of 26 trials (19 %) in the 'implementation group' but none of the trials in the 'control group' included all domains of the core set. In trials with all other types of interventions including NSAIDS, a full set of domains was used in eight out of 25 trials (32 %) of the 'implementation group' and in one out of 36 trials (3 %) of the 'control group'.
RCTs evaluating DMARDs, biological drugs or systemic glucocorticoids
Domains
The usage of the domains and instruments recommended for the DC-ART scenario is shown in Table 3 . The domain Records identified through database searching Medline (n =369) Embase (n = 197) (n =566)
Screening
Included
Eligibility Identification
Records screened after duplicates removed (n =441)
Records excluded by abstract (n =271)
Full-text articles assessed for eligibility (n =170)
Full-text articles excluded (n = 48): no clinical outcome (n=15) duplicate (n=2) no full text available (n=23) no RCT (n=2) ≤80% axial SpA (n=6) Articles included in qualitative synthesis (n = 127 articles covering 99 RCTs) Fig. 1 Flow chart of the results of the search strategy, describing the reasons for study exclusion 'patient's global assessment' was assessed in about 60 % of the trials (61 vs 67 %; p=0.8) in 'implementation' and 'control' groups. The domain 'spine radiograph' was only assessed in the 'implementation group' (23 vs 0 %; p=0.07). Three domains were substantially more frequently represented in the 'implementation group' as compared to the 'control group' and were even assessed in all trials of the 'implementation group': 'physical function' (100 vs 42 %; p≤0.001), 'peripheral joints/entheses' (100 vs 33 %; p≤0.001) and 'fatigue' (100 vs 0 %; p≤0.001). Four domains also show a high level of usage in the 'implementation group' but were already high in the 'control group': 'pain' (100 vs 92 %), 'spinal mobility' (81 vs 92 %), 'spinal stiffness' (100 vs 92 %) and 'acute phase reactants' (96 vs 83 %).
Instruments
A number of instruments had a low usage in the trials of both the 'implementation group' and 'control group': 'night pain' (42 vs 33 %) and 'joint count' (42 vs 33 %). With respect to the instrument 'joint count', the number of joints assessed was very different ranging from 22 to 70 joints. Three instruments were substantially more frequently reported in the 'implementation' vs the 'control group': Bath Ankylosing Spondylitis Functional Index ('BASFI') (100 vs 8 %), 'BASMI' (54 vs 0 %) and 'CRP' (92 vs 59 %). The domain 'global pain' was frequently used in both groups (100 vs 92 %). Concerning 'radiographic progression', two instruments-'mSASSS' and 'BASRI'-were used but were only reported in 'implementation' trials. The instruments 'MASES' and 'Berlin', both for the domain 'peripheral joint/entheses', were evaluated only after 2001. Although the most commonly selected instrument to evaluate 'physical function' in the 'implementation group' was the 'BASFI', in many trials, more than one instrument was used to evaluate this domain.
RCTs evaluating NSAIDs, physical therapy and miscellaneous interventions
Domains and instruments
These results on implementation in RCTs evaluating NSAIDs, physical therapy and miscellaneous interventions are shown in Table 4 . The domain patient's global assessment showed a low percentage of usage in the 'implementation group' and even lower than that in the trials of the 'control group' (36 vs 51 %). 'Physical function' and 'fatigue' were significantly more frequently used in the trials of the 'implementation group' as compared to the 'control group': (92 vs 23 %, p=<0.001, and 84 vs 17 %, p<0.001), respectively, whereas the domain pain had a high representation in the trials of both groups (96 vs 89 %).
Regarding the instruments, we found that 'Dougados FI' and 'night pain' had a rather low representation in trials of both groups: (8 vs 9 %) and (20 vs 44 %), respectively. The representation of 'BASFI' (88 vs 14 %) and 'BASMI' (52 vs 0 %), however, improved significantly in 'implementation trials', while global 'pain' (96 vs 86 %) remained at a high level in both groups.
Evolution of usage of domains and instruments over time
In order to illustrate the evolution of the representation of domains and instruments, Fig. 2a , b was constructed. (2) b Intervention in these studies: DMARDs (3) and biological drugs (23) c If BASDAI was reported, we considered that the domains (fatigue, pain, stiffness and peripheral joint/entheses) were performed, although these were not separately reported d If BASMI was reported, we considered that the domain spinal mobility and the instruments (lateral spinal flexion, tragus-to-wall distance, modified Schober, intermalleolar distance and cervical rotation) were performed, although these were not separately reported
ASAS-endorsed response criteria and other outcomes
Since the ASAS response criteria and partial remission criteria were published in 2001 (ASAS 20 and ASAS partial remission criteria) and in 2004 (ASAS 40 and ASAS 5/6), only studies published 2 years after those dates (n=45 and n=33, respectively) were included in the analyses (in this context, only trials from the 'implementation group' were investigated). ASAS 20 response criteria were reported in 40 % of the trials (18 out of 45 trials), ASAS 40 in 45 % (15 out of 33) of the trials, ASAS 5/6 in 30 % (10 out of 33) and ASAS partial remission in 22 % (10 out of 45). The reported percentages for each response criteria are different mainly due to the publication date and the implementation time. The number of trials reporting the response criteria is not the same, e.g. ASAS 20 (45 trials) and ASAS 40 (30 trials). In Table 5 , the ASAS response criteria are presented according to the type of intervention. A high level of usage was found in trials with biological drugs [ASAS 20 (73 %), ASAS 40 (93 %), ASAS partial remission (53 %) and ASAS 5/6 (60 %)]. BASDAI 50 was reported as response measure only in implementation trials (25 %; n=13).
Discussion
This study confirms the implementation of the ASAS/OMERACT core set in randomized clinical trials after the original publication. A substantial improvement in the utilization of ASAS-endorsed domains and, to a lesser extent, of ASAS-endorsed instruments over time is evident. Additionally, an increasing number of RCTs have reported a full or nearly full spectrum of ASAS core domains, which was observed across all interventions. Overall, the utilization of the DC-ART core set is very good and better than that of the SMARD core set. p values are for comparison between assessments performed in 'control' and 'implementation' groups a Intervention in these studies: NSAIDs (25), physical therapy (5) and miscellaneous (6) b Intervention in these studies: NSAIDs (4), physical therapy (13), balneotherapy (5) and miscellaneous (3) c If BASDAI was reported, we considered that the domains (fatigue, pain, spinal stiffness and peripheral joint/enthuses) were performed, although it was not separately reported d If BASMI was reported, we considered that the domain spinal mobility and the instruments (lateral spinal flexion, tragus-to-wall distance, modified Schober, intermalleolar distance and cervical rotation) were performed, although these were not separately reported Fig. 2 The domains 'physical function', 'peripheral joint/entheses', 'fatigue' and 'spine radiograph' improved substantially over time. 'Physical function' is considered as an important outcome measure for the evaluation of disease evolution and, additionally, is a domain relevant to the patient and is reported by a high proportion of studies (92 %). Moreover, 'BASFI' included by ASAS as the preferred instrument is far more often used as a method for the evaluation of 'physical function' (88 %).
A similar trend of utilization was observed with the domain 'spine radiograph'. With the expectation that there would be a positive effect by treatment on structural damage, it stimulated the inclusion of this domain in more recent trials. The domains 'acute phase reactants, pain, spinal mobility and spinal stiffness' were already frequently used before the publication of the core sets, and this has remained unchanged. The only domain that did not show an increased usage over time is 'patient's global assessment' (61 % for DC-ART and 36 % for SMARD core set).
Regarding the specific instruments to measure each domain, there is clearly more homogeneity, as non-endorsed instruments that were used frequently in the past are not used so often anymore after the introduction of the core set. Nevertheless, the overall level of implementation of specific instruments still leaves room for further improvement, especially for the SMARD core set.
A remarkable improvement in the usage of domains and instruments is attributable to RCTs with biological treatments, intended for drug registration purposes. These RCTs are usually of very high methodological quality, and trial planning teams that were responsible for the choice of primary and secondary outcome measures have scrutinized the literature to search for the best set of instruments. In this context, the ASAS core set, as such, may have contributed to the performance of these trials, to a more transparent drug registration process and to a better acceptance of new treatments in the field.
The ASAS response and partial remission criteria are intended for use in the evaluation of drug treatment. Therefore, it could be expected that the best implementation is seen in trials evaluating biological therapies, and this is most obvious with regard to the use of the ASAS 40 and ASAS 5/6, which were developed to assess relatively better responses, as could be expected to occur in efficient drugs such as biological drugs.
As a possible limitation of our analysis is that the time period of 2 years after the publication as a cut-off point between the two groups of trials is an arbitrary choice and may not be sufficient to assess the implementation properly. Indeed, we have found that there is a further increase in implementation over the years. The strength of this study is that a primary and very comprehensive search of the entire literature was conducted, specifically aiming at the population of interest.
All domains and instruments that have been used in the trials should be reported. Interestingly, we have found that sometimes, domains and instruments were used but not reported separately. For example, the domain 'fatigue', which is included in the 'BASDAI', as well as specific instruments included in the 'BASMI' were not always reported separately. There might be several explanations for this. A trivial one is space constraint, but online appendices may resolve this problem. Another possibility is that authors only report positive results. Most likely, however, authors may not understand the purpose of core sets: Reporting outcomes of a trial in a homogeneous manner, with the aim to avoid publication bias and the possibility to compare measures across trials.
In conclusion, this study provides evidence for the utilization of the ASAS/OMERACT core set in RCTs of both DC-ART and SMARD, especially to the use of the domains and, to a lesser extent, to the use of specific instruments. However, there is room for improvement, aiming at reporting the complete core set and their instruments.
